Other laboratory findings included hypofibrinogenemia (< 1.5 g/L, 40/101, 39.6%), hypertriglyceridemia (> 3 mmol/L, 36/101, 35.6%), prolonged activated partial thromboplastin time (10 s greater than control) (45/101, 44.6%), prolonged prothrombin time (3 s greater than control) (16/101,15.8%), elevated soluble CD25 (> 2400 U/mL, 87/98, 88.8%) and hemophagocytosis in the bone marrow (57/97, 58.8%). The gene discussed is F2; the disease is hypertriglyceridemia.